The immunoproteasome: A novel drug target for autoimmune diseases

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 74-79

  Basler, Michael ^a,b   Mundt, Sarah ^a   Bitzer, Annegret ^a   Schmidt, Christian ^a   Groettrup, Marcus ^a,b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b UNIVERSITY OF KONSTANZ   (Switzerland)

Author keywords

Autoimmune diseases; Immunoproteasome; Proteasome inhibitors; Protein degradation; Ubiquitin

Indexed keywords

IMMUNOPROTEASOME; IMMUNOPROTEASOME SUBUNIT LMP7; ONX 0914; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; LMP7 PROTEIN;

ARTICLE; AUTOIMMUNE DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASES; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84953344733     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. HUBER EM, BASLER M, SCHWAB R et al.: Immuno-and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell 2012; 148: 727-38.
2. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
3. NIEDERMANN G, GEIER E, LUCCHIARIHARTZ M, HITZIGER N, RAMSPERGER A, EICHMANN K: The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. Immunol Rev 1999; 172: 29-48.
4. BASLER M, LAUER C, BECK U, GROETTRUP M: The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009; 183: 6145-50.
5. CHEN WS, NORBURY CC, CHO YJ, YEWDELL JW, BENNINK JR: Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J Exp Med 2001; 193: 1319-26.
6. BASLER M, YOUHNOVSKI N, Van Den BROEK M, PRZYBYLSKI M, GROETTRUP M: Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J Immunol 2004; 173: 3925-34.
7. BASLER M, MOEBIUS J, ELENICH L, GROETTRUP M, MONACO JJ: An Altered T Cell Repertoire in MECL-1-Deficient Mice. J Immunol 2006; 176: 6665-72.
8. OSTERLOH P, LINKEMANN K, TENZER S et al.: Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc Natl Acad Sci USA 2006; 103: 5042-7.
9. GROETTRUP M, KIRK CJ, BASLER M: Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 2010; 10: 73-8.
10. BASLER M, BECK U, KIRK CJ, GROETTRUP M: The antiviral immune response in mice devoid of immunoproteasome activity. J Immunol 2011; 187: 5548-57.
11. BASLER M, LAUER C, MOEBIUS J et al.: Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation. J Immunol 2012; 189: 1868-77.
12. KINCAID EZ, CHE JW, YORK I et al.: Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 2012; 13: 129-35.
13. ZAISS DM, de GRAAF N, SIJTS AJ: The proteasome immunosubunit multicatalytic endopeptidase complex-like 1 is a T-cell-intrinsic factor influencing homeostatic expansion. Infect Immun 2008; 76: 1207-13.
14. MOEBIUS J, van den BROEK M, GROETTRUP M, BASLER M: Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur J Immunol 2010; 40: 3439-49.
15. MUCHAMUEL T, BASLER M, AUJAY MA et al.: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009; 15: 781-7.
16. KALIM KW, BASLER M, KIRK CJ, GROETTRUP M: Immunoproteasome Subunit LMP7 Deficiency and Inhibition Suppresses Th1 and Th17 but Enhances Regulatory T Cell Differentiation. J Immunol 2012.
17. KREMER M, HENN A, KOLB C et al.: Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol 2010; 185: 5549-60.
18. BASLER M, MUNDT S, MUCHAMUEL T et al.: Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 2014; 6: 226-38.
19. BASLER M, DAJEE M, MOLL C, GROETTRUP M, KIRK CJ: Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol 2010; 185: 634-41.
20. FitzPATRICK LR, KHARE V, SMALL JS, KOLTUN WA: Dextran sulfate sodium-induced colitis is associated with enhanced low molecular mass polypeptide 2 (LMP2) expression and is attenuated in LMP2 knockout mice. Dig Dis Sci 2006; 51: 1269-76.
21. SCHMIDT N, GONZALEZ E, VISEKRUNA A et al.: Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010; 59: 896-906.
22. ICHIKAWA HT, CONLEY T, MUCHAMUEL T et al.: Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type i interferon and autoantibody secreting cells. Arthritis Rheum 2012; 64: 493-503.
23. NAGAYAMA Y, NAKAHARA M, SHIMAMURA M, HORIE I, ARIMA K, ABIRU N: Prophylactic and therapeutic efficacies of a selective inhibitor of the immunoproteasome for Hashimoto' s thyroiditis, but not for Graves' hyperthyroidism, in mice. Clin Exp Immunol 2012; 168: 268-73.
24. HO YK, BARGAGNA-MOHAN P, WEHENKEL M, MOHAN R, KIM KB: LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol 2007; 14: 419-30.
25. van SWIETEN PF, SAMUEL E, HERNANDEZ RO et al.: A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg Med Chem Lett 2007; 17: 3402-5.
26. KUHN DJ, HUNSUCKER SA, CHEN Q, VOORHEES PM, ORLOWSKI M, ORLOWSKI RZ: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009; 113: 4667-76.
27. SINGH AV, BANDI M, AUJAY MA et al.: PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011; 152: 155-63.
28. KASAM V, LEE NR, KIM KB, ZHAN CG: Selective immunoproteasome inhibitors with nonpeptide scaffolds identified from structurebased virtual screening. Bioorg Med Chem Lett 2014; 24: 3614-7.
29. de BRUIN G, HUBER EM, XIN BT et al.: Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes. Journal of medicinal chemistry 2014; 57: 6197-209.
30. KOROLEVA ON, PHAM TH, BOUVIER D et al.: Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle. Biochimie 2015; 108: 94-100.
31. BASLER M, KIRK CJ, GROETTRUP M: The immunoproteasome in antigen processing and other immunological functions. Curr Opin Immunol 2013; 25: 74-80.
32. CONNER EM, BRAND S, DAVIS JM et al.: Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282: 1615-22.
33. OBENG EA, CARLSON LM, GUTMAN DM, HARRINGTON WJ, Jr., LEE KP, BOISE LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-16.
34. NEUBERT K, MEISTER S, MOSER K et al.: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748-55.
35. ALEXANDER T, SARFERT R, KLOTSCHE J et al.: The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74: 1474-8.
36. CODARRI L, GYULVESZI G, TOSEVSKI V et al.: RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-7.
37. El-BEHI M, CIRIC B, DAI H et al.: The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011; 12: 568-75.
38. FRAUSTO RF, CROCKER SJ, EAM B, WHITMIRE JK, WHITTON JL: Myelin oligodendrocyte glycoprotein peptide-induced experimental allergic encephalomyelitis and T cell responses are unaffected by immunoproteasome deficiency. J Neuroimmunol 2007; 192: 124-33.
39. NATHAN JA, SPINNENHIRN V, SCHMIDTKE G, BASLER M, GROETTRUP M, GOLDBERG AL: Immuno-and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 2013; 152: 1184-94.